Peptic Ulcer Disease and Gastrointestinal Bleeding

Peptic ulcer disease (PUD) represents a breach in the mucosal surface of the stomach or duodenum extending through the muscularis mucosae. The condition affects approximately 4-5 million Americans annually, with a lifetime prevalence of 5-10%.

[KEY_CONCEPT] The pathophysiology involves an imbalance between aggressive factors (acid, pepsin, H. pylori) and protective factors (mucus, bicarbonate, prostaglandins, mucosal blood flow).

Primary Etiologies

H. pylori infection accounts for 60-90% of duodenal ulcers and 60-70% of gastric ulcers. This gram-negative spiral bacterium produces urease, allowing survival in acidic environments, and releases cytotoxins that damage the gastric epithelium.

NSAID-induced ulceration occurs through:

• COX-1 inhibition → decreased prostaglandin E2 → reduced mucus and bicarbonate production
• Direct epithelial toxicity
• Impaired platelet aggregation increasing bleeding risk

[HIGH_YIELD] Zollinger-Ellison syndrome should be considered in patients with:

• Multiple or recurrent ulcers
• Ulcers in unusual locations (jejunum)
• Family history of MEN-1
• Refractory disease despite appropriate therapy

Gastrointestinal Bleeding Classification

Upper GI bleeding originates proximal to the ligament of Treitz:

• Peptic ulcer disease (40-50%)
• Esophageal varices (15-20%)
• Mallory-Weiss tears (5-10%)
• Boerhaave syndrome (<1%)

Lower GI bleeding originates distal to the ligament of Treitz:

• Diverticulosis (30-40%)
• Angiodysplasia (20-30%)
• Inflammatory bowel disease (10-15%)
• Malignancy (5-10%)

Peptic Ulcer Disease Symptoms

Duodenal ulcers typically present with:

• Epigastric pain that improves with eating
• Pain occurring 2-5 hours postprandially
• Nocturnal awakening (1-3 AM)
• Relief with antacids or proton pump inhibitors

Gastric ulcers characteristically cause:

• Epigastric pain that worsens with eating
• Early satiety and weight loss
• Nausea and vomiting

[CLINICAL_PEARL] The classic "food-pain" relationship (duodenal ulcers improve with eating, gastric ulcers worsen) is present in only 50-60% of patients.

Upper GI Bleeding Presentations

[HIGH_YIELD] Hematochezia from upper GI bleeding indicates massive hemorrhage (>1000 mL) with rapid transit time.

Lower GI Bleeding Presentations

• Hematochezia: Most common presentation
• Maroon-colored stools: Suggests right-sided colonic bleeding
• Cramping abdominal pain: Often accompanies inflammatory causes
• Painless bleeding: Characteristic of diverticulosis and angiodysplasia

Risk Stratification Signs

High-risk features requiring immediate intervention:

• Hemodynamic instability (SBP <100 mmHg, HR >100 bpm)
• Active bleeding or recent bleeding with high rebleeding risk
• Comorbid conditions (cirrhosis, anticoagulation)
• Age >65 years with bleeding

[CLINICAL_PEARL] Orthostatic vital signs are unreliable in elderly patients and those on beta-blockers or with autonomic dysfunction.

Laboratory Assessment

Initial laboratory studies for suspected GI bleeding:

• Complete blood count (hemoglobin may be normal acutely)
• Basic metabolic panel (BUN/creatinine ratio >36 suggests upper GI bleeding)
• Liver function tests
• Coagulation studies (PT/INR, aPTT)
• Type and crossmatch

[KEY_CONCEPT] BUN/creatinine ratio >36 suggests upper GI bleeding due to protein digestion and absorption of blood.

H. pylori Testing

Non-invasive Testing Options

[HIGH_YIELD] Test-and-treat strategy is appropriate for patients <60 years with dyspepsia and no alarm features.

Endoscopic Evaluation

Upper Endoscopy Indications

Upper Endoscopy Algorithm:

Upper GI Bleeding ↓ Hemodynamically stable? ↙ ↘ YES NO ↓ ↓ Within Urgent EGD 24 hours within 12 hours ↓ Risk stratify using Forrester Classification

Forrester Classification for Peptic Ulcer Bleeding:

• Ia: Active arterial bleeding (90% rebleed risk)
• Ib: Active oozing (10-20% rebleed risk)
• IIa: Non-bleeding visible vessel (40-50% rebleed risk)
• IIb: Adherent clot (20-30% rebleed risk)
• IIc: Flat pigmented spot (5-10% rebleed risk)
• III: Clean ulcer base (<5% rebleed risk)

Lower Endoscopy Approach

Colonoscopy is the diagnostic modality of choice for lower GI bleeding:

• Perform within 24 hours for ongoing bleeding
• Adequate bowel preparation essential
• Therapeutic interventions available

[CLINICAL_PEARL] CT angiography should be considered for massive lower GI bleeding when colonoscopy is technically difficult or when bleeding rate exceeds 0.5 mL/min.

Differential Diagnosis

Upper GI Bleeding Differential

1. Peptic ulcer disease (most common)
2. Esophageal varices (in cirrhotic patients)
3. Mallory-Weiss tear
4. Boerhaave syndrome
5. Esophagitis
6. Neoplasm

Lower GI Bleeding Differential

1. Diverticulosis
2. Angiodysplasia
3. Inflammatory bowel disease
4. Infectious colitis
5. Ischemic colitis
6. Neoplasm

Acute GI Bleeding Management

Initial Stabilization

Acute GI Bleeding Management Algorithm:

Patient Presentation ↓ ABC Assessment ↓ Two large-bore IV access ↓ Fluid resuscitation (Target Hgb 7-9 g/dL) ↓ PPI therapy ↓ Risk stratification ↙ ↘ High risk Low risk ↓ ↓ Urgent Elective endoscopy endoscopy (<12 hrs) (<24 hrs)

[HIGH_YIELD] Restrictive transfusion strategy (Hgb 7-9 g/dL) is preferred unless patient has active coronary artery disease.

Pharmacologic Management

Proton Pump Inhibitors (PPIs):

• High-dose IV PPI: Omeprazole 80 mg IV bolus, then 8 mg/hr infusion
• Continue until endoscopic evaluation
• Transition to oral PPI after hemostasis achieved

Octreotide (for suspected variceal bleeding):

• 50 mcg IV bolus, then 50 mcg/hr infusion
• Continue for 3-5 days
• Reduces splanchnic blood flow

H. pylori Eradication

First-Line Therapy Options

[CLINICAL_PEARL] Bismuth quadruple therapy is preferred first-line treatment in areas with clarithromycin resistance >15%.

Treatment Failure Management

Second-line options:

• Bismuth quadruple therapy (if not used initially)
• Levofloxacin triple therapy: PPI + amoxicillin + levofloxacin
• Culture-guided therapy

Confirmation of eradication:

• Urea breath test or stool antigen 4-6 weeks after completion
• Avoid PPIs ×2 weeks, antibiotics ×4 weeks before testing

NSAID-Related Ulcer Management

Risk Stratification

High GI risk factors:

• Age >65 years
• History of PUD or GI bleeding
• Concurrent anticoagulation
• High-dose or multiple NSAIDs
• Concurrent corticosteroids

Prevention Strategies

NSAID Risk Management:

Patient requires NSAID ↓ Assess GI risk ↙ ↘ Low risk High risk ↓ ↓ Standard • COX-2 selective + PPI NSAID • OR standard NSAID + PPI • OR avoid NSAID

[HIGH_YIELD] COX-2 selective inhibitors alone do NOT provide adequate gastroprotection in high-risk patients.

Endoscopic Therapy

Upper GI Bleeding Interventions

Injection therapy:

• Epinephrine 1:10,000 (temporary hemostasis)
• Should be combined with thermal or mechanical therapy

Thermal therapy:

• Bipolar electrocoagulation
• Argon plasma coagulation
• Heater probe

Mechanical therapy:

• Hemostatic clips
• Band ligation

Lower GI Bleeding Interventions

• Injection therapy: Epinephrine for active bleeding
• Clip application: For visible vessels
• Thermal therapy: Argon plasma coagulation for angiodysplasia
• Band ligation: For rectal varices

Peptic Ulcer Complications

Major Complications (MNEMONIC: HOPS)

1. Hemorrhage (15-20% of ulcers)
2. Obstruction (2-5% of ulcers)
3. Perforation (2-5% of ulcers)
4. Stenosis/Stricture (rare)

Hemorrhage Management

Rebleeding risk factors:

• Age >65 years
• Hemodynamic instability at presentation
• Comorbid illness (ASA class ≥III)
• Endoscopic findings (Forrester Ia, Ib, IIa, IIb)

[HIGH_YIELD] Rebleeding occurs in 10-20% of patients within 72 hours; highest risk in first 24 hours.

Management of rebleeding:

1. Repeat endoscopic therapy
2. If second endoscopic failure → surgery or interventional radiology
3. Consider transcatheter arterial embolization for surgical candidates

Perforation

Clinical presentation:

• Sudden onset severe abdominal pain
• Board-like rigidity
• Pneumoperitoneum on imaging

Management:

• Immediate surgical consultation
• NPO, IV fluids, antibiotics
• Nasogastric decompression

Gastric Outlet Obstruction

Symptoms:

• Early satiety
• Postprandial vomiting
• Weight loss
• Succussion splash

Evaluation:

• Upper endoscopy
• Barium swallow if endoscopy contraindicated
• CT scan to assess for malignancy

Long-term Monitoring

H. pylori Follow-up

Confirmation of eradication required for:

• PUD with complications
• Gastric ulcers
• Persistent symptoms
• High-risk patients

Testing timeline:

• 4-6 weeks after treatment completion
• Use urea breath test or stool antigen
• Avoid confounding medications

Gastric Ulcer Surveillance

[CLINICAL_PEARL] All gastric ulcers require follow-up endoscopy to document healing and exclude malignancy, unlike duodenal ulcers in patients <45 years.

Follow-up endoscopy:

• 8-12 weeks after initial diagnosis
• Biopsy any non-healing ulcers
• Consider surgical evaluation for non-healing ulcers

NSAID Management

For patients requiring continued NSAIDs:

• Lowest effective dose and duration
• COX-2 selective agents in high-risk patients
• Concurrent PPI therapy
• Regular monitoring for complications

Prevention Strategies

Primary Prevention

For high-risk NSAID users:

• PPI prophylaxis (omeprazole 20 mg daily)
• Consider COX-2 selective inhibitors
• Evaluate need for NSAID therapy regularly

H. pylori screening:

• Consider in high-prevalence populations
• Before initiating long-term NSAID therapy
• Family history of gastric cancer

Secondary Prevention

After ulcer healing:

• H. pylori eradication confirmation
• Discontinue NSAIDs if possible
• Long-term PPI for high-risk patients
• Lifestyle modifications (smoking cessation, alcohol reduction)

[KEY_CONCEPT] Maintenance PPI therapy is indicated for patients with recurrent ulcers, failed H. pylori eradication, or continued high-risk medication use.

Short-term Outcomes

Mortality Rates

Upper GI bleeding:

• Overall mortality: 5-10%
• Peptic ulcer bleeding: 3-5%
• Variceal bleeding: 15-20%
• Age >65 years significantly increases mortality risk

Lower GI bleeding:

• Overall mortality: 2-4%
• Generally better prognosis than upper GI bleeding
• Mortality increases with hemodynamic instability

[HIGH_YIELD] Rockall Score predicts mortality and rebleeding risk in upper GI bleeding based on age, shock, comorbidities, diagnosis, and endoscopic findings.

Rebleeding Rates

Without endoscopic therapy:

• High-risk lesions (Forrester Ia, Ib): 80-90%
• Moderate-risk lesions (Forrester IIa, IIb): 40-50%
• Low-risk lesions (Forrester IIc, III): <10%

With appropriate endoscopic therapy:

• Rebleeding rates reduced by 50-70%
• Most rebleeding occurs within 72 hours

Long-term Prognosis

H. pylori Eradication Outcomes

Successful eradication provides:

• 90-95% reduction in ulcer recurrence
• Decreased risk of gastric cancer
• Resolution of dyspeptic symptoms in most patients
• Cost-effective long-term strategy

[CLINICAL_PEARL] Ulcer recurrence after successful H. pylori eradication is <5% per year, compared to 60-70% without eradication.

NSAID-Associated Ulcer Outcomes

Risk factors for poor outcomes:

• Advanced age (>75 years)
• Multiple comorbidities
• Continued NSAID use
• Failure to use gastroprotection

Preventive strategies effectiveness:

• PPI + NSAID: 70-80% risk reduction
• COX-2 selective + PPI: 85-90% risk reduction
• Misoprostol + NSAID: 40-50% risk reduction

Quality of Life Impact

Functional Outcomes

Post-bleeding recovery:

• Most patients return to baseline function within 4-6 weeks
• Elderly patients may have prolonged recovery
• Iron deficiency anemia common, requiring supplementation

Chronic PUD impact:

• Dietary modifications often unnecessary after healing
• Psychological impact of recurrent symptoms
• Work productivity may be affected during active disease

Follow-up Care

Routine monitoring includes:

• Symptom assessment at 4-6 weeks
• Complete blood count if anemic at presentation
• H. pylori eradication confirmation when indicated
• Endoscopic surveillance for gastric ulcers

Prognostic Scoring Systems

Glasgow-Blatchford Score (GBS)

Pre-endoscopic risk stratification:

• Score 0-1: Low risk, consider outpatient management
• Score ≥2: High risk, requires hospitalization
• Includes: BUN, hemoglobin, vital signs, melena, syncope

[KEY_CONCEPT] Glasgow-Blatchford Score of 0 has 99% negative predictive value for need for intervention.

AIMS65 Score

Simplified mortality prediction:

• Albumin <3.0 g/dL
• INR >1.5
• Mental status alteration
• Systolic BP <90 mmHg
• Age >65 years

Mortality by score:

• 0-1 points: <1% mortality
• 2 points: 5-10% mortality
• 3+ points: >10% mortality

Prevention of Recurrence

Key strategies for optimal outcomes:

• Complete H. pylori eradication when present
• Discontinue NSAIDs when possible
• Appropriate gastroprotection for high-risk patients
• Lifestyle modifications (smoking cessation)
• Regular follow-up and monitoring

[HIGH_YIELD] Most peptic ulcers heal completely with appropriate therapy, and recurrence is rare with successful H. pylori eradication and NSAID cessation.